Business
Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference.
About this update from Aeolus Pharmaceuticals Inc
[{"type":"text","content":"\nAeolus Pharmaceuticals to Present at LD Micro Invitational Conference\n\nAeolus Pharmaceuticals to Present at LD Micro Invitational Conference\n\n\n MISSION VIEJO, CA--(Marketwired - May 23, 2016) - \n Aeolus Pharmaceuticals, Inc.\n (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it will be presenting at the 6th annual LD Micro Invitational on Tuesday, June 7th at 9:00AM PDT / 12 Noon EDT at the Luxe Sunset Boulevard Hotel in Los Angeles. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors. Mr. Cavalier will provide an update on Aeolus' development pipeline, including its $118.4 million advanced R & D contract with the Biomedical Advanced Research and Development Authority (\"BARDA\"), a division of the U.S. Department of Health and Human Services. The BARDA contract funds the advanced development of AEOL-10150 (\"10150\") for the treatment of the pulmonary and delayed effects of acute radiation exposure (\"Lung-ARS\") following a nuclear detonation or accident. 10150 has demonstrated efficacy in multiple mouse and non-human primate Lung-ARS studies and is being developed under the FDA Animal Rule, which allows the use of animal studies in indications where human efficacy trials are not possible. 10150 is also being developed for the treatment of Idiopathic Pulmonary Fibrosis (\"IPF\") and for use in oncology to reduce the side effects of radiation therapy for solid tumors. The Company is also developing AEOL 11114 as a treatment for Parkinson's disease with support from the Michael J. Fox Foundation for Parkinson's disease. A third compound, AEOL 20415 is in development for the treatment of infectious diseases.\"We are honored to have Aeolus Pharmaceuticals present at the conference.\" stated Chris Lahiji, President of LD Micro.A webcast of the presentation will be available live on the Company's website at www.aolsrx.com. The presentation will also be archived for viewing after the conference.\n \n About AEOL 10150\n \n AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue da...